| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,296,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the uterine healthcare needs of women. Co. provides a suite of products for the treatment of structural and non-structural causes of abnormal uterine bleeding in most uterine anatomies. Co.'s devices are used by obstetrician-gynecologists across various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. Co.'s product offerings include Minerva ES Endometrial Ablation System; Genesys HTA Endometrial Ablation System; Symphion Tissue Removal System; and Resectr Tissue Resection Device.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
24,437,927 |
| Total Buy Value |
$0 |
$0 |
$0 |
$5,000,000 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cohen Daniel |
Director |
– • – |
2023-03-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
122,189,638 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2023-02-09 |
4 |
B |
$0.20 |
$5,000,000 |
D/D |
24,437,927 |
34,437,052 |
2.45 |
- |
|
| Accelmed Partners Ii L.p. |
|
– – • |
2023-02-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
122,189,638 |
|
- |
|
| Geiger Uri |
|
– • • |
2023-02-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
122,189,638 |
|
- |
|
| Sung Derrick |
Director |
– • – |
2022-07-19 |
4 |
A |
$2.30 |
$199,999 |
D/D |
86,956 |
86,956 |
|
- |
|
| Jung Joel R |
CFO |
• – – |
2022-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,198 |
220,730 |
|
- |
|
| Skalnyi Evgueni V. |
VP Medical Affairs |
• – – |
2022-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
49,755 |
244,725 |
|
- |
|
| Filloux Dominique J. |
COO |
• – – |
2022-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
60,198 |
266,289 |
|
- |
|
| Clapper David M |
President and CEO |
• • – |
2022-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
229,732 |
323,232 |
|
- |
|
| Filloux Dominique J. |
COO |
• – – |
2021-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,500 |
206,091 |
|
- |
|
| Skalnyi Evgueni V. |
VP Medical Affairs |
• – – |
2021-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,250 |
194,970 |
|
- |
|
| Jung Joel R |
CFO |
• – – |
2021-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,500 |
160,532 |
|
- |
|
| Clapper David M |
President and CEO |
• • – |
2021-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
93,500 |
93,500 |
|
- |
|
| Clapper David M |
President and CEO |
• • – |
2021-12-13 |
4 |
B |
$4.94 |
$123,435 |
I/I |
25,000 |
642,660 |
2.66 |
- |
|
| Jaffe Ross A Md |
Director |
– • – |
2021-10-26 |
4/A |
A |
$0.00 |
$0 |
I/I |
1,673,700 |
10,473 |
|
- |
|
| Jaffe Ross A Md |
Director |
– • – |
2021-10-26 |
4/A |
A |
$0.00 |
$0 |
I/I |
286,226 |
1,789 |
|
- |
|
| Jaffe Ross A Md |
Director |
– • – |
2021-10-26 |
4 |
A |
$0.00 |
$0 |
I/I |
94,755 |
94,755 |
|
- |
|
| Behbahani Ali |
Director |
– • – |
2021-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,487 |
8,487 |
|
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2021-10-26 |
4 |
B |
$12.00 |
$15,600,000 |
D/D |
1,300,000 |
9,999,125 |
2.45 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2021-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,699,125 |
8,699,125 |
|
- |
|
| Novo A/s |
10% Owner |
– – • |
2021-10-26 |
4 |
B |
$12.00 |
$6,960,000 |
D/D |
580,000 |
2,057,132 |
2.45 |
- |
|
| Novo A/s |
10% Owner |
– – • |
2021-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
1,477,132 |
1,477,132 |
|
- |
|
| Skalnyi Evgueni V. |
VP Medical AffairsOfficer |
• – – |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
174,720 |
|
- |
|
| Clapper David M |
President and CEOOfficer |
• • – |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
617,660 |
|
- |
|
| Coste Catherine |
Director |
– • – |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
79,787 |
|
- |
|
27 Records found
|
|
Page 1 of 2 |
|
|
